Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisors LLC lessened its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 4.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 247,792 shares of the biopharmaceutical company's stock after selling 11,722 shares during the quarter. Capital Investment Advisors LLC's holdings in Bristol-Myers Squibb were worth $14,015,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brookstone Capital Management grew its stake in Bristol-Myers Squibb by 11.0% during the 4th quarter. Brookstone Capital Management now owns 186,155 shares of the biopharmaceutical company's stock valued at $10,529,000 after acquiring an additional 18,516 shares in the last quarter. Trust Co. of Toledo NA OH boosted its holdings in shares of Bristol-Myers Squibb by 21.8% during the fourth quarter. Trust Co. of Toledo NA OH now owns 46,679 shares of the biopharmaceutical company's stock worth $2,640,000 after purchasing an additional 8,341 shares during the period. Fiduciary Alliance LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $253,000. Aprio Wealth Management LLC lifted its position in Bristol-Myers Squibb by 72.9% in the 4th quarter. Aprio Wealth Management LLC now owns 8,282 shares of the biopharmaceutical company's stock worth $468,000 after buying an additional 3,493 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of Bristol-Myers Squibb by 6.5% during the 4th quarter. Czech National Bank now owns 439,749 shares of the biopharmaceutical company's stock valued at $24,872,000 after buying an additional 26,747 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity

In other news, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were acquired at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company's stock, valued at $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.48 on Monday, reaching $55.35. 7,107,596 shares of the company were exchanged, compared to its average volume of 9,632,166. The firm has a market capitalization of $112.26 billion, a PE ratio of -15.42, a PEG ratio of 15.20 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The stock's fifty day moving average price is $57.44 and its 200 day moving average price is $51.56. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the firm posted $2.00 EPS. The business's revenue was up 8.4% compared to the same quarter last year. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.48%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's payout ratio is -69.08%.

Analyst Ratings Changes

Several brokerages recently issued reports on BMY. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and increased their price objective for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Bank of America reiterated a "neutral" rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. BMO Capital Markets raised their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a "market perform" rating in a research report on Tuesday, November 12th. Morgan Stanley boosted their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.